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Estrogen exerts its biological effects through two signal pathways, the genomic and non-genomic pathway, both of which contrib-
ute to cell homeostasis. The non-genomic pathway has been suggested to be important in estrogen-induced cardio-, neuron-, and 
osteoprotection, and confers the ability of the cell to rapidly respond to its environment. The effects of the non-genomic pathway 
are the regulation of different cellular processes, such as proliferation, survival, apoptosis, and other functions in diverse cell-types. 
The proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), is now known as a modulator of the estrogen receptors, and is 
also a novel coregulator of the non-genomic signal pathway with various functions. Therefore, the evaluation of the molecular 
crosstalk between PELP1 and the non-genomic pathway may lead to the development of functionally selective estrogen receptor 
modulators which can participate in the multiple functions of estrogen signaling in reproductive tissues and other organs. 
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The estrogen 17- estradiol (E2) binds to its receptors and 
cofactors to mediate various hormonal effects which play 
roles in a wide variety of biological processes in multiple 
organs including the brain, breast, the cardiovascular system, 
uterus and bone [1–4]. Estrogen receptors (ER)α and ER are 
the primary members of the estrogen receptor super-family. 
The mechanisms of ER and ER ligand binding, their di-
merization, the association with coactivators or corepressors, 
and transcriptional regulation through binding to target 
genes, are well-known and are typically referred to as “ge-
nomic” actions. More recently, E2 and other steroids have 
been found to have rapid, cytoplasmic actions as well, 
which are called “non-genomic” actions. The genomic ac-
tions are related to maintaining basic cellular functions, 
including chromatin remodeling and cell cycle progression 
[5]. The non-genomic actions confer the ability of the cell to 
dynamically respond to physiological or pathological 
changes [6].  
Recently, PELP1 has been reported to play a role in E2 
signaling in multiple studies. PELP1 acts as an important 
protein that regulates the effects of estrogen on other sig-
naling pathways. Previous studies showed that PELP1 acts 
as a scaffolding protein and coregulator of the ER, and par-
ticipates in both the genomic and non-genomic actions of E2 
signaling [7,8]. Therefore, the evaluation of the interactions 
between PELP1 and estrogen signaling may lead to the de-
velopment of functionally selective ER modulators that can 
separate the beneficial, prodifferentation effects in bone, the 
cardiovascular system, and the central nervous system, and 
the detrimental proliferative effects in reproductive tissues 
and organs.  
1  Estrogen signaling pathways 
Several studies have shown that the biological effects of E2 
are mediated through two signaling pathways [9]. One is 
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referred to as “classical” or “genomic” pathway and is di-
rectly related to the ability of E2 to regulate the expression 
of genes containing estrogen response-enhancer (ERE) se-
quences in their promoters [10]. When E2 binds to the ER, 
the ligand-activated ER translocates to the nucleus, binds to 
ERE target genes and stimulates gene transcription. The 
other pathway is referred to as the “non-classical”, “rapid”, 
or “non-genomic” pathway and is directly related to the 
ability of estrogen signaling to participate in cytoplasmic 
and membrane-mediated signaling events. The non-ge-      
nomic pathway intersects with other cell-signaling phos-
phorylation cascades. The process is insensitive to inhibitors 
of RNA and protein biosynthesis and, in some cases, can 
take place in the absence of a nucleus. The non-genomic 
(transcription-independent) activation of several cytosolic 
factors (Src, MAPK, PKC and AKT) is how E2 mediates its 
biological functions [11]. 
The idea that estrogen binding to the ER only mediates 
estrogen-target gene transcription is likely an oversimplifi-
cation. In fact, recent studies have revealed signaling inter-
actions between the ER and other signal transduction path-
ways such as “non-genomic pathway”. In some studies, the 
ER non-genomic pathway has been suggested to play a key 
role in estrogen-induced cardio-, neuro-, and osteoprotec-
tion [12]. 
2  Coregulator of estrogen signaling pathways  
The estrogen signaling pathway is highly dependent on and 
regulated by coregulatory proteins. It is generally accepted 
that some of the diverse functions of estrogen depends on 
the differential recruitment of coregulators to the ligand- 
bound ER complex [13]. Coregulators function by partici-
pating in a wide variety of actions including the remodeling 
and modification of chromatin. Nuclear receptor coregula-
tors function as major regulators of hormone signaling be-
cause they have the ability to convey signals to the nuclear 
receptors and target gene promoters. The direct effects of 
estrogen signaling and the differential recruitment of coreg-
ulators might prime nuclear coactivators or corepressors and 
the chromatin to set the stage for ER gene transcription, 
thus defining the outcome of the cellular response to E2. 
The most recently identified and studied ER coregulator is 
the proline-, glutamic acid-, and leucine-rich protein 1 
(PELP1). 
3  PELP1 
3.1  Structure of PELP1 
PELP1 was first identified as a 160-kD interacting protein 
in a GST-SH2 domain pull-down assay. Previous work on 
PELP1 had shown that this protein contains several motifs 
and domains that are commonly present in transcriptional 
coactivators, including nuclear receptor-interacting boxes 
(LXXLL motifs), a zinc finger, a glutamic acid-rich domain, 
and two proline-rich domains. A unique feature of PELP1 is 
its histone-binding region. The proline-rich domains contain 
PXXP motifs which can interact with signaling proteins 
containing SH3 domains. LXXLL motifs can interact with 
nuclear receptors including the estrogen receptor, the an-
drogen receptor, the glucocorticoid receptor, and the pro-
gesterone receptor, in a ligand-dependent manner [14]. 
LXXLL motifs 4 and 5 primarily mediate the binding of 
PELP1 to the AF2 domain of the ER [8]. Thus PELP1 is 
also called the coregulator of the ER. Other motifs associate 
with the histones and can recruit other ER coregulators with 
histone acetyltransferase activity and bind to the SH2, FHA, 
SH3, PDZ, and WW domains. Also, PELP1 can interact 
with important components related to cell cycle progression, 
including CDK4, cyclin D1, and the retinoblastoma protein 
(pRb) [15]. Previous studies [11,14] showed that PELP1 
could interact with the cytosolic kinases c-Src, phosphati-
dylinositol-3 kinase (PI3K), and a number of other signaling 
components, including the epidermal growth factor receptor 
(EGFR), signal transducer and activator of transcription 
(STAT), and the hepatocyte growth factor-regulated tyro-
sine kinase substrate (HRS). PELP1 is also suggested to 
play a role in modulating local chromatin structure in the 
vicinity of nuclear receptor promoters with different signal-
ing components. 
3.2  Expression of PELP1 
PELP1 is expressed in a wide variety of tissues with the 
highest levels of expression noted in the brain [16], mam-
mary gland, ovaries, and uterus [8,11,17]. Previous studies 
showed that the function of PELP1 was determined by its 
expression level and cellular localization [17]. In the rat 
brain, a study reported high-intensity PELP1 staining colo-
calized with ER [15]. It is also highly expressed in the 
known target organs of estrogen/steroid signaling with the 
highest levels of expression found during pregnancy [8]. 
PELP1 is also highly expressed in normal mammary gland 
[11]. PELP1 contains a central consensus nuclear localiza-
tion sites and exhibits both nuclear and cytoplasmic locali-
zation in a variety of cells in the body [8]. In normal tissues, 
PELP1 has been shown to reside in both the nucleus and 
cytoplasm [18]. In hormonally responsive tissues, PELP1 
predominantly resides in the nucleus, and localization in the 
cytoplasm is reduced [19]. Within the nuclear compartment, 
PELP1 localizes to the nucleoplasm, chromatin, and nuclear 
matrix [8]. 
3.3  PELP1 and the estrogen non-genomic signaling 
pathway  
In some E2 positive tissues, such as bone and endothelial 
cells, estrogen signaling is transduced predominantly through 
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the non-genomic pathway which is also called rapid signal 
pathway [20]. This signaling allows for rapid changes in 
cell shape and size. The effects occur within minutes, are 
not blocked by transcriptional and translational inhibitors, 
and can be activated in many different types of cells by 
membrane-impermeable ligands. The rapid signaling often 
initiates at the cell’s surface through a mechanism different 
from that mediated by the ER and its ability to recruit 
coregulators. Rapid rearrangement of the action cytoskeleton 
generally depends on the binding of external stimuli to mem-
brane associated receptors, and is mediated via the subse-
quent rapid action of different protein phosphates and ki-
nases [6], including G-proteins, tyrosine kinase c-Src, cave-
olin-1, heat shock protein 90, and PELP1. Previous studies 
have shown that PELP1 plays an important role in estrogen 
signaling pathways [5,14], especially in non-genomic sig-
naling pathway [21]. PELP1 was found to be an activator of 
the non-genomic effects of ER providing a mechanism for 
coupling ligand binding with the rapid E2-dependent activa-
tion of Src and the downstream MAPK signaling cascade. 
Src has been identified as a crucial molecule downstream of 
the ER through its physical interaction with the receptor, 
and might mediate estrogen’s rapid action. The MAPK 
pathway is involved in the control of many fundamental 
cellular functions that include differentiation, apoptosis, 
motility, and metabolism. Previous studies showed that 
Src/MAPK played a fundamental role in both growth factor 
and E2-stimulated cell growth, and regulates both cell pro-
liferation and survival [22]. The ER interacts with Src’s 
SH2 domain, and this complex is stabilized by PELP1. Thus 
PELP1 mediates a critical step in the activation of c-Src and 
subsequent MAPK signaling. Moreover, PELP1 also coor-
dinates and promotes complex formation with ER, and 
PI3K, which also suggests that PELP1 is an important reg-
ulator of cell cycle progression via the PI3K pathway.  
In the rapid signal pathway, PELP1 is considered a scaf-
fold protein, and provides functional cross-talk between the 
growth factor pathways. Cross-talk between growth factor 
and steroid signaling in the cytoplasm and nucleus may 
have a profound impact on complex biological processes 
such as cell growth and proliferation [22,23]. There are four 
independent lines of evidence of cross-talk between the re-
ceptor tyrosine kinase/growth factor and estrogen signaling 
[24,25]. The first is a G-protein-like transactivation of EGFR 
proposed to occur via ER. The second shows a direct in-
teraction of ERα with Shc which acts to couple the activated 
ER to the Ras/ERK pathway. The third is a G-protein and 
Src kinase dependent, EGFR independent pathway. Finally 
there is a cascade involving the interaction of the ER with 
PELP1 or c-Src, which in turn activates Ras to link the ac-
tivated ER to the MAPK pathway. Earlier studies also 
showed that PELP1 promotes growth factor-mediated acti-
vation of ER targets genes. PELP1 also participates in the 
phosphorylation of growth factor which is important in fa-
cilitating PELP1 cross-talk with ER signaling [7].  
4  Conclusion   
PELP1, as a coregulator protein that couples various sig-
naling complexes with the estrogen receptor, plays a key 
role in the extra nuclear actions of hormone receptors and 
thus represents a unique ER-coregulator that participates in 
both the genomic and the non-genomic actions of estrogen 
signaling. PELP1 is recruited to the promoters of ER target 
genes, and enhances the transcription of estrogen target 
genes. In addition, PELP1 plays a role in estrogen-mediated 
regulation of cell cycle progression and differentiation 
through a non-genomic pathway. Future studies are needed 
to address the effect of PELP1 in mediating other effects of 
estrogen signaling.  
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